BioPorto share is markedly up as new CEO for US is hired, and management remains confident at event after strong Q1 report
BioPorto yesterday announced that a new CEO for its US business is appointed who will be responsible for the commercialization process in US of the company’s FDA approved NGAL-test, ProNephro AKI.
Following the announcement, BioPorto today released its 1. quarter report, showing high growth in its NGAL Test for research use only in the US and had management maintain their guidance for 2024. Later, CEO Peter Mørch Eriksen participated in an event with HCA Capital where the CEO presented the report and reiterated high confidence in BioPorto’s ability to successfully commercialize ProNephro AKI as salespeople from BioPorto and test-equipment maker and partner Roche will begin their marketing efforts of ProNephro AKI in the US in the coming quarters.
You can view the event here: Bioporto Q1
Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate visibility subscription agreement./ Henrik Ekman 13:45 08.05.2024
Login required
This content is only available for logged in users
BioPorto
BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.
Read more on company page